Dr. Jessica A. Hellyer
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Colorado School of Medicine, Denver (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 330
Licensed in Washington since 2021, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Colorado School of Medicine, Denver
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
WA license MD61214270 (first issued 2021; expired) · CO license DR.0074593 (first issued 2025; active) -
Internal Medicine Physician
PA license MD470698
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Intermountain Health St. Mary's Regional Hospital Grand Junction, CO
- Montrose Regional Health Montrose, CO
Medical groups
- Montrose Memorial Hospital, Inc (148 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 330
- Services billed
- 111,525
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 13,600 | 17 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 9,460 | 62 |
| Injection, aprepitant, 1 mg | 9,360 | 33 |
| Injection, paclitaxel, 1 mg | 3,805 | 13 |
| Injection, lanreotide, 1 mg | 3,240 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,268 | 66 |
| Injection, granisetron hydrochloride, 100 mcg | 911 | 32 |
| Injection, palonosetron hcl, 25 mcg | 890 | 38 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 519 | 97 |
| Injection of additional new drug or substance into vein | 485 | 74 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Philadelphia, PA | 80 |
| Dexamethasone Other prescribers in Philadelphia, PA | 79 |
| Ondansetron Odt (ondansetron) Other prescribers in Philadelphia, PA | 71 |
| Oxycodone Hcl Other prescribers in Philadelphia, PA | 68 |
| Prochlorperazine Maleate Other prescribers in Philadelphia, PA | 66 |
| Gabapentin Other prescribers in Philadelphia, PA | 46 |
| Prednisone Other prescribers in Philadelphia, PA | 45 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Philadelphia, PA | 42 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Philadelphia, PA | 26 |
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 41 payments worth $2,195 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,160 |
|---|---|
| Janssen Biotech, Inc. | $196 |
| Pfizer Inc. | $84.29 |
| Merck Sharp & Dohme LLC | $71.03 |
| Takeda Pharmaceuticals U.S.A., Inc. | $68.18 |
| AstraZeneca Pharmaceuticals LP | $66.17 |
| Aveo Pharmaceuticals, Inc. | $43.92 |
| Array Biopharma Inc | $43.55 |
| Consulting Fee | $1,160 |
|---|---|
| Food and Beverage | $1,035 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. May 22, 2025 | Consulting Fee | $1,160 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $258,955 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
AstraZeneca Pharmaceuticals LP - A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose …
AstraZeneca UK Limited - A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Beone Medicines Ltd. · Completed · NCT05909904 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.